T-CURX Secures $20 Million Series A Financing to Advance Next-Generation CAR-T Therapies

VCBeat learned that on December 17, 2025, T-CURX announced the successful completion of the first tranche of its Series A financing, raising US$20 million. This round of financing was jointly participated by investors from Europe and Asia. The proceeds will be used to accelerate the clinical development of the company’s non-viral technology platform-based CAR-T therapy in the fields of acute myeloid leukemia (AML) and solid tumors, and to further advance its proprietary in vivo CAR-T technology platform.

This round of financing was led by BiomedVC, with joint investments from Bayern Kapital, HLC (HighLight Capital), and i&i Bio, among other professional institutions. Existing investors also continued to participate.

Dr. Ulf Grawunder, Co-founder and CEO of T-CURX, stated: "I am deeply honored that T-CURX has attracted international investors led by BiomedVC, who possess a strong industry background. This financing will provide financial support for T-CURX’s non-clinical and clinical CAR-T technologies and pipeline projects. It not only validates the high quality of the data demonstrated by T-CURX but also highlights the tremendous potential of our non-viral CAR-T pipelines targeting novel antigens in AML, CLL, and solid tumors. Furthermore, this successful financing further underscores the value of our unique technological approach: combining non-viral CAR vectors with LNP technology to create a more cost-effective and scalable in vivo CAR-T generation platform, aiming to make CAR-T therapy accessible to a broader global patient population."

T-CURX is a German biotechnology company founded in 2017, headquartered in Würzburg. The company is committed to developing the next generation of CAR-T cell therapies by utilizing its cost-effective and scalable non-viral CAR-T cell technology to benefit more cancer patients in urgent need of efficient treatment. The company was incubated from the laboratory of Professor Michael Hudecek of the University of Würzburg, co-founder of T-CURX, and is led by experienced serial entrepreneur and co-founder Dr. Ulf Grawunder as CEO. The company relies on a series of proprietary technologies, including the use of the non-viral Sleeping Beauty transposon system, to achieve efficient and scalable CAR-T cell production.